T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing a 4.5% beneficial ownership position in Elanco Animal Health Inc as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 22,379,405 shares of Elanco Animal Health common stock.
- Percent of class: The 22,379,405 shares represent 4.5% of the outstanding class, according to the filing.
- Sole voting power: The filing reports sole voting power over 22,307,497 shares.
- Sole dispositive power: Sole power to dispose of or direct the disposition of 22,379,405 shares is reported.
- Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
- Event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type "IA") organized in Maryland.
T. Rowe Price Investment Management Discloses Elanco Stake via Amended 13G
T. Rowe Price Investment Management, Inc., a Maryland-incorporated investment adviser with its principal business office at 1307 Point Street, Baltimore, MD 21231, filed Amendment No. 1 to Schedule 13G on November 16, 2026, covering shares of Elanco Animal Health Inc (NYSE:ELAN) common stock (CUSIP 28414H103). The filing was triggered by an event dated September 30, 2026, and was signed by Ellen York, Vice President, on behalf of the firm.
According to the filing, T. Rowe Price Investment Management holds an aggregate beneficial ownership of 22,379,405 shares, equal to 4.5% of the class. The filing reports sole voting power over 22,307,497 shares and sole dispositive power over the full 22,379,405 shares. Shared voting power and shared dispositive power are each listed as 0. The filing notes ownership of 5 percent or less of the class under Item 5.
The filer certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further states that T. Rowe Price Investment Management "hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."
What Was Disclosed
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 22,379,405 shares, or 4.5%, of Elanco Animal Health Inc common stock as of September 30, 2026, with sole voting power over 22,307,497 shares and no shared voting or dispositive power.



Please wait processing your request...